1 / 1

High-Grade Glioma Market

The incidence rate of High-Grade Glioma is 5-10 new diagnoses per 1,000,000 children per year. HGGs accounts for nearly 15-20% of CNS tumours in children and adolescents. It has been observed that HGG is more common in men than in women.<br><br>The key players in the High-Grade Glioma Market includes BioMimetix, Oncoceutics, Inc., Bristol-Myers Squibb, Istari Oncology, Aadi Bioscience, Sumitomo Dainippon Pharma, Novartis, Kazia Therapeutics, and others. <br><br>For more details visit: https://www.delveinsight.com/report-store/high-grade-glioma-market<br>

DelveInsight
Download Presentation

High-Grade Glioma Market

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

    More Related